ALTAY THERAPEUTICS, INC.
Small molecule STAT3 inhibitors for systemic sclerosis and interstitial lung disease
- Sector
- Biotech
- Headquarters
- SAN CARLOS, CA
- Latest Form D
- $15.7M, Oct 2026
- Total capital
- $18.3M
- Federal grants
- $2.6M
- 8 awards · 2022–2024
- Rank in peer group#156 of 326
- Private capital raised
- $15.7M
- 1 Form D · last Oct 2026
- 1 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 10 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$15.7M
- Federal grantHealth and Human S · Phase I · The development of a STAT3 inhibitor for lung scleroderma$300K
- Federal grantNSF · Phase I · SBIR Phase I:Targeting the Root Cause of Ewing’s Sarcoma$275K
- Federal grantHealth and Human S · Phase I · Novel STAT3 inhibitor for overcoming chemoresistant ovarian cancer .$400K
- Federal grantHealth and Human S · Phase I · Novel STAT3 inhibitor for overcoming chemoresistant ovarian cancer .$400K
- Federal grantHealth and Human S · Phase I · Development of a direct DUX4 inhibitor for Facioscapulohumeral Muscular Dystrophy (FSHD)$300K
- Federal grantHealth and Human S · Phase I · Development of a direct DUX4 inhibitor for Facioscapulohumeral Muscular Dystrophy (FSHD)$300K
Show 2 earlier federal awards
- Federal grantHealth and Human S · Phase I · The development of a transcriptional inhibitor for lung fibrosis.$299K
- Federal grantHealth and Human S · Phase I · The development of a transcriptional inhibitor for lung fibrosis.$299K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
52months
from ALTAY THERAPEUTICS, INC.’s first federal award to its first private round.
- First federal award · May 2022
- Health and Human S · $299K
- First Form D · Oct 2026
- $15.7M · 1st Form D
- Awards before first raise
- 8 awards
An association in public records, not a cause or a prediction.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grants#156 · top 48%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 0 granted of 10- PendingN-PHENYL-3-(2,5-DIOXOPYRROLIDIN-1-YL)PROPANAMIDE Derivatives And Similar Compounds As DUX4 Inhibitors For The Treatment Of E.g. Neuromuscular DisordersUSPTOApplication 19537121
- Pending2-SUBSTITUTED Thiazole And Benzothiazole Compositions And Methods As DUX4 InhibitorsUSPTOApplication 19243829
- PendingCarbocyclic And Heterocyclic STAT3 Inhibitor Compositions And MethodsUSPTOApplication PCTUS2024055570
Show all 10 patent records
- N-PHENYL-3-(2,5-DIOXOPYRROLIDIN-1-YL)PROPANAMIDE Derivatives And Similar Compounds As DUX4 Inhibitors For The Treatment Of E.g. Neuromuscular DisordersJun 25, 2026 · Application 19537121Pending
- 2-SUBSTITUTED Thiazole And Benzothiazole Compositions And Methods As DUX4 InhibitorsOct 9, 2025 · Application 19243829Pending
- Carbocyclic And Heterocyclic STAT3 Inhibitor Compositions And MethodsApplication PCTUS2024055570Pending
- Carbocyclic And Heterocyclic DUX4 Inhibitor Compositions And MethodsApplication PCTUS2024052155Pending
- 2-SUBSTITUTED Thiazole And Benzothiazole Compositions And MethodsApplication PCTUS2023086566Pending
- 2-SUBSTITUTED Thiazole And Benzothiazole Compositions And MethodsApplication 63616498Pending
- Carbocyclic And Heterocyclic STAT3 Inhibitor Compositions And MethodsApplication 63597904Pending
- Carbocyclic And Heterocyclic DUX4 Inhibitor Compositions And MethodsApplication 63545126Pending
- 2-SUBSTITUTED Thiazole And Benzothiazole Compositions And MethodsApplication 63436362Pending
- Carbocyclic And Heterocyclic STAT3 Inhibitor Compositions And MethodsApplication 19584887Pending
Related companies, and why
- ALTAY THERAPEUTICS, INCShares a founder: Ali R Ozes
- Sepragen CorporationSimilar federal contract value in Biotech · null in contracts
- A-Alpha Bio, Inc.Similar federal contract value in Biotech · null in contracts
- Odorcept, LLCSimilar federal contract value in Biotech · null in contracts
- Elektrofi IncSimilar federal contract value in Biotech · null in contracts
- OMNICYTE, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .